Pfizer and South Korea's Samsung Biologics Ink $900M Partnership for Biosimilar Production: Details
Portfolio Pulse from Vandana Singh
Pfizer Inc and Samsung Biologics have signed two agreements for the long-term manufacturing of Pfizer's multiproduct biosimilar portfolio, worth $897 million. The deals include a $193 million deal and a $704 million deal, making it Samsung Biologics' most significant single contract since its inception in 2011. Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multiproduct biosimilar portfolio covering oncology, inflammation, and immunology. The deals will last through 2029.
July 05, 2023 | 12:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer has signed two significant deals with Samsung Biologics for the long-term manufacturing of its biosimilar portfolio. This will provide Pfizer with additional capacity for large-scale manufacturing, potentially boosting its production and revenues.
The deals with Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing. This could potentially increase Pfizer's production and revenues in the long term, which could positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100